To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC81738 | WEE1/PKMYT1-IN-3 |
WEE1/PKMYT1-IN-3 is the axial chiral M configuration of WEE1/PKMYT1-IN-1. WEE1/PKMYT1-IN-1 is a potent and orally active WEE1 and PKMYT1 inhibitor. WEE1/PKMYT1-IN-1 shows antiproliferation activity.
More description
|
|
| DC80217 | Anti-Influenza agent 10 |
Anti-Influenza agent 10 (Compound 41) is an influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor. Anti-Influenza agent 10 exhibits potent antiviral activity against A/PR/8/34(H1N1) with an IC50 of 0.29μM and a KD of 4.11 μM. Anti-Influenza agent 10 can inhibit the assembly of the viral RdRp complex by disrupting the protein interaction between PA and PB1 subunits, thereby blocking the transcription and replication of the viral genome. Anti-Influenza agent 10 shows significant broad-spectrum effects on multiple influenza virus strains, such as H3N2, H3N8 and H9N2 with IC50 values of 3.96, 1.91 and 1.45 μM. Anti-Influenza agent 10 can be used for the research of influenza A Virus Infection.
More description
|
|
| DC80207 | Antibacterial agent 328 |
Antibacterial agent 328 is a enoyl-ACP reductase (InhA) inhibitor and antimycobacterial agent. Antibacterial agent 328 blocks mycolic acid biosynthesis in Mycobacterium tuberculosis. Antibacterial agent 328 acts on both drug-resistant and drug-susceptible Mycobacterium tuberculosis strains. Antibacterial agent 328 exhibits favorable pharmacokinetic properties, drug-likeness, and a safety-related selectivity index. Antibacterial agent 328 can be used for research on tuberculosis.
More description
|
|
| DC77966 | Pegpleranib |
Pegpleranib is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.
More description
|
|
| DC77965 | Pegpleranib sodium |
Pegpleranib sodium is a pegylated DNA aptamer that selectively binds to PDGF-BB and PDGF-AB homodimers and heterodimers, interrupting the interaction with their associated tyrosine kinase receptors.
More description
|
|
| DC77193 | Xanthinol |
Xanthinol is a potent modulator of tumor hemodynamics.
More description
|
|
| DC77192 | RPR-101511 |
RPR-101511 is a 3-substituted quinoline derivative. RPR-101511 is a PDGF receptor tyrosine kinase inhibitor (IC50: 0.001-0.02 μM).
More description
|
|
| DC77191 | 2-Methyl-3-phenylquinoxaline |
2-Methyl-3-phenylquinoxaline (compound 38) is a potent platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) inhibitor with modest inhibitory activity against PDGFR kinase in intact cells (IC50 greater than 100 μM).
More description
|
|
| DC48363 | DMPQ dihydrochloride Featured |
DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM.
More description
|
|
| DC72751 | CT52923 Featured |
CT52923 is a selective, orally active platelet-derived growth factor receptor (PDGFR) antagonist. CT52923 also is an ATP-competitive inhibitor. CT52923 can be used for the research variety of pathological diseases, including atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
More description
|
|
| DC50121 | GTPL-6019 Featured |
GTPL6019, also know nas IUN54940, DGFR Tyrosine Kinase Inhibitor III, is a PDGFR inhibitor with potential anticancer activity.
More description
|
|
| DC8494 | Toceranib phosphate(SU 11654) Featured |
Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
More description
|
|
| DC7329 | Toceranib(SU 11654; PHA 291639) Featured |
Toceranib(SU 11654; PHA 291639) is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
More description
|
|
| DC7389 | CP-673451 Featured |
CP 673451 is a selective inhibitor of PDGFRα/β with IC50 of 10 nM/1 nM, exhibits >450-fold selectivity over other angiogenic receptors, has antiangiogenic and antitumor activity.
More description
|
|
| DC7799 | AZD2932 Featured |
AZD-2932 is a high affinity inhibitor of VEFGR-2 and PDGFR.
More description
|
|
| DC71152 | AG 370 |
AG 370, an indole tyrphostin, is a potent PDGF-induced mitogenesis inhibotor (IC50 of 20 μM). AG 370 displays weak inhibition of the EGF receptor.
More description
|
|
| DC5079 | Orantinib (TSU-68) Featured |
SU6668 has greatest potency against PDGFR autophosphorylation with Ki of 8 nM, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR.
More description
|
|
| DC3145 | Sunitinib base Featured |
Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
More description
|
|
| DC28402 | Tyrphostin AG1433 Featured |
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation.
More description
|
|
| DC44101 | Seralutinib Featured |
Seralutinib (GB002) is an inhaled Pdgfr kinase inhibitor. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
More description
|
|
| DC44006 | GZD856 formic |
GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4 nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity.
More description
|
|
| DC40408 | N-(p-Coumaroyl) Serotonin |
N-(p-Coumaroyl) Serotonin is a polyphenol isolated from the seeds of safflower and has antioxidative, anti-atherogenic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits PDGF-induced on phosphorylation of PDGF receptor and Ca2+ release from sarcoplasmic reticulum. N-(p-Coumaroyl) Serotonin ameliorates atherosclerosis and distensibility of the aortic wall in vivo and is usually used for the atherosclerosis research.
More description
|
|